Skip to content

Study of Next Generation Sequencing in the diagnosis of immunocompromised patients with bilateral pulmonary lesions

Study of Next Generation Sequencing in the diagnosis of immunocompromised patients with bilateral pulmonary lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17013320
Enrollment
Unknown
Registered
2017-11-09
Start date
2017-11-17
Completion date
Unknown
Last updated
2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICH with bilateral pulmonary lesions

Interventions

Gold Standard:The final clinical diagnosis is a comprehensive analysis of the results of conventional examination, the NGS, possible pathological detection and the change of treatment and response to
Index test:NGS detection

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. At the age of no less than 18; 2. Immunocompromised (details is as following); 3. Bilateral pulmonary military lesions, nodule-like lesions(<1cm), patch or patch-fusion lesions, or diffuse interstitial lesions can be found in imagological examination; And need etiological examination; 4. Inform the consent form. The Immunocompromised standard: 1. Neutropenia: count =500/ul (0.5*10^9/L). 1)Hematological malignancy2)Anticancer agent use3)Drug induced 2. Humoral immunodeficiency: ?-Globulin=500mg/dl(5g/l), Dysfunction of specific antibody production. Hematological malignancy; After splenectomy; Anti-CD20 antibody use; 3. Cellular immunodeficiency: In HIV patients, the CD4 count is=200/ul(0.2*10^9/L); Severity cannot be assessed by the CD4 count in the following: use of immunosuppressants; Use of anticancer agents; Hematological malignancy; Diabetes, renal failure; Use of biological preparations.

Exclusion criteria

Exclusion criteria: 1. With mental illness and can't complete the examination; 2. Taking part in other clinical trials that may affect this trial.

Design outcomes

Primary

MeasureTime frame
the results of etiology detection;

Countries

China

Contacts

Public ContactSong Yuanlin

Zhongshan Hospital, Fudan University

ylsong70@163.com+86 21 64041990-2963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026